Assertio Therapeutics (ASRT) Prices 35M Share Registered Direct Offering at $0.98/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering
February 10, 2021 12:01 AM ESTLAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000 shares of its common stock at a price of $0.98 per share, which is a premium to market based on applicable Nasdaq minimum price rules.
Roth Capital Partners acted as the sole placement agent in connection with the offering.
The registered direct offering is expected to close on February 12, 2021, subject to customary closing conditions. The gross proceeds to the Company from... More



